Upstream Bio (UPB) Expected to Post Quarterly Earnings on Wednesday

Upstream Bio (NASDAQ:UPB) is anticipated to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Upstream Bio to post earnings of ($0.7286) per share and revenue of $0.52 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 7:00 AM ET.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.01. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%. The business had revenue of $0.77 million during the quarter, compared to analysts’ expectations of $0.56 million. On average, analysts expect Upstream Bio to post ($2.84) EPS for the current fiscal year and ($2.77) EPS for the next fiscal year.

Upstream Bio Stock Down 1.8%

NASDAQ:UPB opened at $3.35 on Tuesday. Upstream Bio has a 1 year low of $2.68 and a 1 year high of $33.68. The stock’s 50 day simple moving average is $4.85 and its two-hundred day simple moving average is $9.36.

Analyst Ratings Changes

A number of research firms recently weighed in on UPB. Weiss Ratings raised shares of Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. Truist Financial dropped their price objective on shares of Upstream Bio to $25.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of Upstream Bio in a report on Wednesday, September 2nd. Wall Street Zen downgraded shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, JPMorgan Chase & Co. upped their target price on shares of Upstream Bio from $8.00 to $9.00 and gave the company a “neutral” rating in a research report on Friday, August 14th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Upstream Bio currently has an average rating of “Hold” and a consensus target price of $29.67.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on developing therapies for inflammatory and immune-mediated diseases. The company’s research is centered on targeting pathways involved in type 2 inflammation, which contributes to conditions affecting the respiratory system and other tissues.

Its lead product candidate is verekitug, an investigational, long-acting monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a role in initiating and maintaining allergic and inflammatory responses.